Saltar al contenido
Merck

A 19F-NMR approach using reporter molecule pairs to assess beta-galactosidase in human xenograft tumors in vivo.

NMR in biomedicine (2008-02-22)
Jian-Xin Yu, Vikram D Kodibagkar, Li Liu, Ralph P Mason
RESUMEN

Gene therapy has emerged as a promising strategy for treatment of various diseases. However, widespread implementation is hampered by difficulties in assessing the success of transfection in the target tissue and the longevity of gene expression. Thus, there is increasing interest in the development of non-invasive in vivo reporter techniques to assay gene expression. We recently demonstrated the ability to detect beta-galactosidase activity in stably transfected human prostate tumor xenografts in mice in vivo using 19F NMR. We now extend the studies to human MCF7 breast cancer cells growing as xenografts in nude mice. Moreover, by using two spectrally resolved reporters (o-fluoro-p-nitrophenyl-beta-D-galactopyranoside and an isomer), two tumors could be interrogated simultaneously revealing lacZ transgene activity in a stably transfected tumor versus no activity in a wild-type tumor. Most significantly, hydrolytic activity observed by 19F NMR corresponded to differential activity in lacZ-expressing tumors.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
β-Galactosidase from Aspergillus oryzae, ≥8.0 units/mg solid